These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33669809)

  • 21. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
    Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
    J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
    Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
    Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.
    Cappato S; Giacopelli F; Ravazzolo R; Bocciardi R
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome.
    Pignolo RJ; Wang H; Kaplan FS
    Front Endocrinol (Lausanne); 2019; 10():908. PubMed ID: 31998237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.
    Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P
    Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.
    Takahashi M; Katagiri T; Furuya H; Hohjoh H
    Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.
    de Gorter DJ; Jankipersadsing V; Ten Dijke P
    Curr Pharm Des; 2012; 18(27):4087-92. PubMed ID: 22630080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
    Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
    Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
    Xie C; Jiang W; Lacroix JJ; Luo Y; Hao J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
    Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
    J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
    Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
    Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.
    Towler OW; Shore EM; Xu M; Bamford A; Anderson I; Pignolo RJ; Kaplan FS
    Eur J Med Genet; 2017 Jul; 60(7):399-402. PubMed ID: 28473268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.
    Le VQ; Wharton KA
    Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
    Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
    J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva.
    Khan F; Yu X; Hsiao EC
    Biomedicines; 2021 Feb; 9(2):. PubMed ID: 33562570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation.
    Lin H; Ying Y; Wang YY; Wang G; Jiang SS; Huang D; Luo L; Chen YG; Gerstenfeld LC; Luo Z
    Biochim Biophys Acta Mol Cell Res; 2017 Dec; 1864(12):2369-2377. PubMed ID: 28847510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
    Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
    Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.